Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.

Translational neurodegeneration - 16 Oct 2020

von Linstow Christian U, Gan-Or Ziv, Brundin Patrik

Abstract excerpt

Parkinson's disease (PD) is characterized by motor deficits and a wide variety of non-motor symptoms. The age of onset, rate of disease progression and the precise profile of motor and non-motor symptoms display considerable individual variation. Neuropathologically, the loss of substantia nigra dopaminergic neurons is a key feature of PD. The vast majority of PD patients exhibit alpha-synuclein aggregates in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosylceramidase

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Mutation

Share to Parkinson Disease

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 33066808
DOI: 10.1186/s40035-020-00218-x
PMCID: PMC7565766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.PMID 33066808Read ↗

Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.Semantic proximity Read ↗

GBA1-and LRRK2-directed Treatments: The Way Forward.Semantic proximity Read ↗

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.Semantic proximity Read ↗

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.Semantic proximity Read ↗

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies.Semantic proximity Read ↗

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.Semantic proximity Read ↗

Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical PipelineSemantic proximity Read ↗

The genetic background of Parkinson's disease and novel therapeutic targets.Semantic proximity Read ↗

Precision medicine for Parkinson’s disease: The subtyping challengeSemantic proximity Read ↗

An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.Semantic proximity Read ↗

Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.